Effect of Black seed on Menopause

Effect of Nigella sativa supplementation on quality of life, Menopausal symptoms and metabolic syndrome among menopausal women

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013111615414N1

Enrollment

Registered

2014-02-20

Start date

2014-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Menopausal symptoms. Condition 2: Diabetes. Other obstetric conditions, not elsewhere classified Diabetes mellitus

Interventions

Intervention 1: Intervention group: Nigella sativa Capsule 2gr/day. Intervention 2: Control Group: Placebo.

Prevention

Placebo

Intervention group: Nigella sativa Capsule 2gr/day

Control Group: Placebo

Eligibility

Sex/Gender

Female

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria Menopausal women; aged between 45 to 65 years old; who agreed to participate in the study ;living in yasuj. Exclusion criteria Induced menopause following to surgery, chemotherapy or radiotherapy; taking steroid hormones in previous 3 months; taking anti hypertensive, anti diabetic or anti hyperlipidemic drugs; history of uncontrolled hypertension, MI,or diagnosed cancers.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Menopausal symptoms. Timepoint: at baseline and end of study. Method of measurement: Green Climacteric Scale.	—

Secondary

Measure	Time frame
Quality of Life. Timepoint: at baseline and at the end of study. Method of measurement: SF-36 questionnaire.;Cholesterol. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;Triglyceride. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;LDL. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;HDL. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;FBS. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;17ß Stradiol. Timepoint: at baseline and at the end of study. Method of measurement: pg/dl.;FSH. Timepoint: at baseline and at the end of study. Method of measurement: miu/ml.;LH. Timepoint: at baseline and at the end of study. Method of measurement: miu/ml.;Blood pressure. Timepoint: at baseline and at the end of study. Method of measurement: mmHg.;Weight. Timepoint: at baseline and at the end of study. Method of measurement: kg.;Height. Timepoint: at baseline and at the end of study. Method of measurement: cm.;BMI. Timepoint: at baseline and at the end of study. Method of measurement: kg/m2.;Body composition. Timepoint: at baseline and at the end of study. Method of measurement: Percent.	—

Measure

Time frame

Quality of Life. Timepoint: at baseline and at the end of study. Method of measurement: SF-36 questionnaire.;Cholesterol. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;Triglyceride. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;LDL. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;HDL. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;FBS. Timepoint: at baseline and at the end of study. Method of measurement: mg/dl.;17ß Stradiol. Timepoint: at baseline and at the end of study. Method of measurement: pg/dl.;FSH. Timepoint: at baseline and at the end of study. Method of measurement: miu/ml.;LH. Timepoint: at baseline and at the end of study. Method of measurement: miu/ml.;Blood pressure. Timepoint: at baseline and at the end of study. Method of measurement: mmHg.;Weight. Timepoint: at baseline and at the end of study. Method of measurement: kg.;Height. Timepoint: at baseline and at the end of study. Method of measurement: cm.;BMI. Timepoint: at baseline and at the end of study. Method of measurement: kg/m2.;Body composition. Timepoint: at baseline and at the end of study. Method of measurement: Percent.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaadat Parhizkar

Yasuj University of Medical Sciences

parhizkarsa@gmail.com+98 74 1222 9224

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026